Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene

Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory tract infection for which no vaccine or antiviral treatment is available. The RSV NS1 protein seems to antagonize the host interferon (IFN) response; however, its mechanism is unknown. Here, we used a plasmid-borne small interfering RNA targeting the NS1 gene (siNS1) to examine the role of NS1 in modulating RSV infection. RSV replication was reduced in A549 cells, but not IFN–deficient Vero cells, transfected with siNS1. siNS1 induced upregulated expression of IFN-β and IFN-inducible genes in A549 cells. siNS1-transfected human dendritic cells, upon RSV infection, produced elevated type-1 IFN and induced differentiation of naive CD4+ T cells to T helper type 1 (TH1) cells. Mice treated intranasally with siNS1 nanoparticles before or after infection with RSV showed substantially decreased virus titers in the lung and decreased inflammation and airway reactivity compared to controls. Thus, siNS1 nanoparticles may provide an effective inhibition of RSV infection in humans.

[1]  W. Filipowicz,et al.  Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Welliver.  Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. , 2003, The Journal of pediatrics.

[3]  C. Hall,et al.  Respiratory syncytial virus infections in previously healthy working adults. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  R. Holman,et al.  Bronchiolitis-associated hospitalizations among US children, 1980-1996. , 1999, JAMA.

[5]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[6]  B. Murphy,et al.  Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. , 2002, The Journal of clinical investigation.

[7]  E. Walsh,et al.  Immunity to and frequency of reinfection with respiratory syncytial virus. , 1991, The Journal of infectious diseases.

[8]  R. Lockey,et al.  Genetic Vaccines and Therapy , 2003 .

[9]  A. Osterhaus,et al.  Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development. , 2001, Vaccine.

[10]  R. Lockey,et al.  Intranasal IFN-γ gene transfer protects BALB/c mice against respiratory syncytial virus infection , 1999 .

[11]  R. Silverman,et al.  Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. , 2002, Virology.

[12]  R. Wagner,et al.  Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. , 1993, Nucleic acids research.

[13]  S. Mohapatra.  Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus , 2003, The Pediatric infectious disease journal.

[14]  E. Raz,et al.  Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization , 1996, Science.

[15]  J. Darnell,et al.  Purification and cloning of interferon-stimulated gene factor 2 (ISGF2): ISGF2 (IRF-1) can bind to the promoters of both beta interferon- and interferon-stimulated genes but is not a primary transcriptional activator of either , 1990, Molecular and cellular biology.

[16]  K. Conzelmann,et al.  Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response , 2000, Journal of Virology.

[17]  R. Kole,et al.  Antisense effects in the cell nucleus: modification of splicing. , 2001, Current opinion in molecular therapeutics.

[18]  L. Bont,et al.  Monocyte interleukin-12 production is inversely related to duration of respiratory failure in respiratory syncytial virus bronchiolitis. , 2000, The Journal of infectious diseases.

[19]  P. Sly,et al.  Childhood asthma following hospitalization with acute viral bronchiolitis in infancy , 1989, Pediatric pulmonology.

[20]  P. Collins,et al.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. , 2000, Virology.

[21]  P. Collins,et al.  The NS1 Protein of Human Respiratory Syncytial Virus Is a Potent Inhibitor of Minigenome Transcription and RNA Replication , 1998, Journal of Virology.

[22]  J. Friedland,et al.  Basic epidemiology and immunopathology of RSV in children. , 2000, Paediatric respiratory reviews.

[23]  B. Kjellman,et al.  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. , 2000, American journal of respiratory and critical care medicine.

[24]  Peter L. Collins,et al.  Suppression of the Induction of Alpha, Beta, and Gamma Interferons by the NS1 and NS2 Proteins of Human Respiratory Syncytial Virus in Human Epithelial Cells and Macrophages , 2004, Journal of Virology.

[25]  P. Collins,et al.  Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein , 1999, Journal of Virology.

[26]  Takashi Miyata,et al.  Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes , 1989, Cell.

[27]  R. Lockey,et al.  Recurrent Respiratory Syncytial Virus Infections in Allergen-Sensitized Mice Lead to Persistent Airway Inflammation and Hyperresponsiveness1 , 2000, The Journal of Immunology.

[28]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[29]  J. Mosca,et al.  Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis , 1986, Molecular and cellular biology.

[30]  R. Iggo,et al.  Determinants of interferon-stimulated gene induction by RNAi vectors. , 2004, Differentiation; research in biological diversity.

[31]  R. Iggo,et al.  Induction of an interferon response by RNAi vectors in mammalian cells , 2003, Nature Genetics.

[32]  T. Rothoeft,et al.  Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon‐γ in naïve T cells , 2003 .

[33]  B. Björkstén,et al.  Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. , 1995, Pediatrics.

[34]  W. Calhoun,et al.  Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. , 1997, American journal of respiratory and critical care medicine.

[35]  K. Conzelmann,et al.  Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3 , 2003, Journal of Virology.

[36]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[37]  K. Conzelmann,et al.  Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells , 2002, Journal of Virology.

[38]  P. Pitha,et al.  On the role of IRF in host defense. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[39]  D. Oriot,et al.  Rotavirus and respiratory syncytial virus nosocomial infections in paediatric wards : a 2-year study , 2000 .

[40]  W. König,et al.  Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. , 1994, Immunology.

[41]  H. Jin,et al.  Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. , 2000, Virology.

[42]  S. Mohapatra,et al.  Genetic therapy: on the brink of a new future , 2003, Genetic vaccines and therapy.

[43]  R. Lockey,et al.  Adenovirus-mediated interferon gamma gene therapy for allergic asthma: involvement of interleukin 12 and STAT4 signaling. , 2002, Human gene therapy.

[44]  T. Rothoeft,et al.  Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells. , 2003, Immunology.

[45]  B. Murphy,et al.  Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees , 2000, Journal of Virology.

[46]  Jian Zhang,et al.  Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. , 2002, Human gene therapy.

[47]  A. Fire,et al.  RNA-triggered gene silencing. , 1999, Trends in genetics : TIG.